Chronic treatment with the (iso-)glutaminyl cyclase inhibitor PQ529 is a novel and effective approach for glomerulonephritis in chronic kidney disease.

Kanemitsu, Naotoshi; Kiyonaga, Fumiko; Mizukami, Kazuhiko; Maeno, Kyoichi; Nishikubo, Takashi; Yoshida, Hiroyuki; Ito, Hiroyuki

Kanemitsu, Naotoshi; Kiyonaga, Fumiko; Mizukami, Kazuhiko; Maeno, Kyoichi; Nishikubo, Takashi; Yoshida, Hiroyuki; Ito, Hiroyuki.

Affiliation

Kanemitsu N; Development, Astellas Pharma Inc., 2-5-1, Nihonbashi-Honcho, Chuo-ku, Tokyo, 103-8411, Japan. naotoshi.kanemitsu@astellas.com.
Kiyonaga F; Corporate Advocacy, Astellas Pharma Inc., Chuo-ku, Tokyo, 103-8411, Japan.
Mizukami K; Drug Discovery Research, Astellas Pharma Inc., Tsukuba-shi, Ibaraki, 305-8585, Japan.
Maeno K; Drug Discovery Research, Astellas Pharma Inc., Tsukuba-shi, Ibaraki, 305-8585, Japan.
Nishikubo T; Astellas Innovation Management LLC, 1030 Massachusetts Ave. Suite 310, Cambridge, MA, 02138, USA.
Yoshida H; Drug Discovery Research, Astellas Pharma Inc., Tsukuba-shi, Ibaraki, 305-8585, Japan.
Ito H; Drug Discovery Research, Astellas Pharma Inc., Tsukuba-shi, Ibaraki, 305-8585, Japan.

Naunyn Schmiedebergs Arch Pharmacol ; 394(4): 751-761, 2021 04.

Article in En | MEDLINE | ID: mdl-33159802

Subject(s)
Key words

CCL2/CCR2 axis; Chronic kidney disease; Glomerulonephritis; PQ529; QC/isoQC inhibitor

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Benzimidazoles / Aminoacyltransferases / Protective Agents / Imidazolines / Renal Insufficiency, Chronic / Glomerulonephritis Type of study: Prognostic_studies Limits: Animals Language: En Journal: Naunyn Schmiedebergs Arch Pharmacol Year: 2021 Document type: Article Affiliation country: Japón Country of publication: Alemania

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google